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The aim of this study is to identify and characterize the health economic evaluations (HEEs) of diagnostic tests
conducted in Brazil, in terms of their adherence to international guidelines for reporting economic studies and
specific questions in test accuracy reports. We systematically searched multiple databases, selecting partial and
full HEEs of diagnostic tests, published between 1980 and 2013. Two independent reviewers screened articles
for relevance and extracted the data. We performed a qualitative narrative synthesis. Forty-three articles were
reviewed. The most frequently studied diagnostic tests were laboratory tests (37.2%) and imaging tests (32.6%).
Most were non-invasive tests (51.2%) and were performed in the adult population (48.8%). The intended
purposes of the technologies evaluated were mostly diagnostic (69.8%), but diagnosis and treatment and
screening, diagnosis, and treatment accounted for 25.6% and 4.7%, respectively. Of the reviewed studies, 12.5%
described the methods used to estimate the quantities of resources, 33.3% reported the discount rate applied, and
29.2% listed the type of sensitivity analysis performed. Among the 12 cost-effectiveness analyses, only two studies
(17%) referred to the application of formal methods to check the quality of the accuracy studies that provided
support for the economic model. The existing Brazilian literature on the HEEs of diagnostic tests exhibited
reasonably good performance. However, the following points still require improvement: 1) the methods used to
estimate resource quantities and unit costs, 2) the discount rate, 3) descriptions of sensitivity analysis methods,
4) reporting of conflicts of interest, 5) evaluations of the quality of the accuracy studies considered in the cost-
effectiveness models, and 6) the incorporation of accuracy measures into sensitivity analyses.
KEYWORDS: Costs and Cost Analysis; Cost-Benefit Analysis; Health Care Costs; Diagnostic Tests Routine; Brazil.
Oliveira MR, Leandro R, Decimoni TC, Rozman LM, Novaes HM, De Soarez PC. Systematic Review of Health Economic Evaluations of Diagnostic
Tests in Brazil: How accurate are the results? Clinics. 2017;72(8):499-509
Received for publication on November 3, 2016; First review completed on January 26, 2017; Accepted for publication on March 6, 2017
*Corresponding author. E-mail: patricia.soarez@usp.br
’ INTRODUCTION
Diagnosing is a crucial process that is the basis of clinical
practice and individual care. In the field of collective health,
diagnosis also serves as the basis for decisions relating to
numerous strategies, such as the implementation of screen-
ing, the control of epidemic outbreaks or the organization of
secondary prevention actions (1).
Scientific research in the field of diagnosis involves esti-
mating the accuracy and reliability of measurements. The
costs of diagnostic tests should also be estimated, especially
when new technologies that impose higher costs on health
systems are involved.
Coverage and reimbursement for diagnostic tests face
much higher entry barriers. The lack of evidence about
health and economic outcomes has been cited as a common
reason for unfavourable coverage decisions (2). Health tech-
nology assessment agencies worldwide are increasingly
using information from health economic evaluations (HEEs),
and they have intensified their scrutiny of diagnostic tests
(3). In Brazil, HEEs constitute a relatively new area of scien-
tific research (4).
In 2011, the National Committee for Health Technology
Incorporation of Sistema Único de Saúde (Brazilian Public
Health System [SUS]), CONITEC, began requiring HEEs to
either help inform policy recommendations for the adoption
of new technologies or review the policy recommendations
made by SUS (5). From 2012 to 2015, CONITEC approved
the incorporation of 15 new diagnostic procedures, including
Xpert Mycobacterium tuberculosis (MTB)/rifampicin (RIF) forDOI: 10.6061/clinics/2017(08)08
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tuberculosis diagnosis and positron emission tomography
(PET)/computed tomography (CT) for the diagnosis and
staging of colorectal and lung cancer and the evaluation of
treatment response in Hodgkin’s and non-Hodgkin’s lym-
phoma. Diagnostic procedures represented 17% (15 of 88) of
the new technologies incorporated during this period.
Some Brazilian HEEs have analysed the efficiency of
diagnostic technologies, similar to those performed in other
countries (6-9); however, the characteristics of the body of
HEEs related to diagnostic tests in Brazil remain unknown.
This systematic review focuses on the production of HEEs
in the field of diagnosis and examines how economic models
are implemented in the diagnostic area, thereby identifying
methodological gaps that can be addressed in future studies.
It is of particular interest to examine if and how test accuracy
has been incorporated into economic evaluation models.
Therefore, the objective of this study was to identify and
characterize the HEEs of diagnostic tests conducted in Brazil
in terms of their adherence to international guidelines for
reporting economic studies and specific questions in test
accuracy reports over an extended period.
’ MATERIALS AND METHODS
This systematic review forms part of a larger research pro-
ject that systematically reviewed all HEEs related to Brazil
that were published between 1980 and 2013 (10). This study
is in accordance with the guidelines for the systematic review
of HEEs published by the UK National Health Service (NHS)
Centre for Reviews and Dissemination (11).
Study identification
We searched multiple databases, including Medline (via
PubMed), Excerpta Medica, the Latin American and Carib-
bean Health Sciences Literature database, the Scientific
Electronic Library Online, the database of the Centre for
Reviews and Dissemination, the NHS Economic Evaluation
Database, the NHS Health Technology Assessment database,
Bireme and the Health Economics database of the Brazilian
Virtual Library of Health. We searched the following citation
indexes: Scopus, Web of Science, and the Brazilian Network
for the Evaluation of Health Technologies. We also perfor-
med manual searches based on the reference lists of included
articles and all issues of the Brazilian Journal of Health
Economics (BJHE), which was a non-indexed journal in the
databases mentioned above in 2013. The search strategy
combined subject headings (Medical Subject Headings
[MeSH] and Embase subject headings [EMTREE]) and free
text terms ("Health Economics" OR "Economics, Hospital"
OR "Economics, Medical" OR "Economics, Nursing" OR
"Economics, Pharmaceutical" OR "Economics" OR "costs and
cost analysis" OR "Cost" OR "Cost savings" OR "Cost of
illness" OR "Analyses, Cost-Benefit" OR "Analysis, Cost-
Benefit" OR "Cost-Benefit Analyses" OR "Cost Benefit
Analysis" OR "Analyses, Cost Benefit" OR "Analysis, Cost
Benefit" OR "Cost Benefit Analyses" OR "Cost Effectiveness
"OR" Effectiveness, Cost "OR" cost effectiveness analysis
"OR" cost-Benefit Date" OR "cost Benefit Date" OR "Date,
Cost-Benefit" OR "cost Benefit" OR "Benefits and Costs" OR
"Costs and Benefits") for the "economic/cost" concept with
subject headings (MeSH and EMTREE) and free text terms
("Brazil" OR "Brazilian" OR "Brazi*") for the "Brazil" concept.
All searches were limited to 1980-2013. The Medline full
electronic search strategy is described in Appendix 1.
Study selection
Articles were included if they were partial or full economic
evaluations, according to the classification devised by Drum-
mond et al. (12), if they addressed a diagnostic test, if they
were conducted in a Brazilian setting, and if at least one of
the authors was affiliated with an institution in Brazil.
Studies were considered partial HEEs if they examined
only costs (cost description), described the costs of a parti-
cular disease to society (cost of illness), described the costs
and outcomes of a single service or programme (cost-
outcome description), described the financial consequences
of technology adoption (budget impact analysis [BIA]) or
compared only the costs of two or more interventions (cost
analysis). Studies were considered full HEEs if they com-
pared the costs and consequences of two or more health
care intervention alternatives, including cost-consequences
analysis (CCA), cost-minimization analysis (CMA), cost-
effectiveness analysis (CEA), cost-utility analysis (CUA) and
cost-benefit analysis (CBA).
Data extraction
Two reviewers (TCD and RL), working independently,
selected studies and extracted data using a template devel-
oped specifically for this study. The data extracted from each
study included the following: year and journal of publica-
tion; type of economic evaluation; category of diagnostic test
(laboratory tests, imaging, rapid tests or microorganism
culture); purpose of the technology assessed (diagnosis,
screening, or treatment); the type of affiliation of the first
author; the geographical location of the first author; conflicts
of interest, as defined by Valachis et al. (13); estimates of cost-
effectiveness; and the conclusion of the study (favourable,
unfavourable, or neutral). For full HEEs, we also recorded
whether the studies contained information on diagnostic test
accuracy to answer the following questions: a) Was the accu-
racy of each test defined and incorporated into the model?
b) Were the test accuracy parameters subjected to any
sensitivity analysis? c) Was the quality of the evidence from
the primary research used to estimate the model parameters
of the accuracy test subjected to a quality assessment?
Disagreements regarding the extracted data were resolved
by consensus or through consultation with a third reviewer
(PCS).
For studies in which the cost year was not specified, we
assumed that the cost year was the same as the year of pub-
lication, a strategy that has been adopted in previous reviews
of the literature (14). The monetary values of the results were
compared to the year’s Brazilian Produto Interno Bruto
(gross domestic product [PIB]) per capita, which is available
from the Brazilian Institute for Geography and Statistics
(15).
Quality assessment
The methodology for the quality reporting of individual
studies was assessed using some items of the Consolidated
Health Economic Evaluation Reporting Standards (CHEERS)
(16).
Data synthesis
A qualitative narrative synthesis was conducted, and the
study characteristics are summarized in the figures and sum-
mary tables.
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Data analysis was performed with descriptive statis-
tics, such as absolute frequencies (raw counts) for each
category of the discrete variable and relative frequencies
(proportions or percentages of the total number of obser-
vations).
’ RESULTS
We identified 535 HEEs related to Brazil that were pub-
lished in 1980-2013 (Figure 1). Of those 535 studies, 43 (8%)
addressed diagnostic tests (17-59). The number of studies
Figure 1 - Flow diagram of the process used to select HEEs related to diagnostic tests in Brazil, 1983-2013.
*HEEs: health economic evaluations.
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and the proportion of full HEEs relative to the proportion
of partial HEEs increased during the period under study
(Figure 2). Of the 43 HEEs related to diagnostic tests, the
majority (74.4%, 32/43) were published in the last ten years
(i.e., between 2005 and 2013), and 19 (44.2%) were full HEEs.
Table 1 shows an overview of the main characteristics
of the diagnostic tests addressed in the 43 selected studies.
The technologies were applied to multiple clinical areas,
including oncology, cardiology, endocrinology and infectious
diseases. The most commonly evaluated tests were labora-
tory tests (37.2%, 16/43) and imaging tests (32.6%, 14/43).
Most were non-invasive tests (51.2%, 22/43) and were
utilized in the adult population (46.5%, 20/44). In terms of
the intended purposes of the technologies evaluated, most
(69.8%, 30/43) were diagnostic; diagnostic and treatment
accounted for 25.6% (11/43), and screening, diagnostic and
treatment accounted for 4.7% (2/43).
The most common study design was CEA (27.9%, 12/43),
and the least common were CUA (2.3%, 1/43) and CMA
(2.3%, 1/43). Among the partial HEEs, the most common
study design was cost-analysis (25.6%, 11/43), followed by
cost-description (18.6%, 8/43).
The majority (55.8%, 24/43) of the HEEs were published in
national journals. Analysing the geographic distribution of
the affiliations of the first authors revealed a concentration of
HEEs from south-eastern Brazil, which accounted for 74.4%
(32/43) of the studies identified. The first authors had the fol-
lowing types of affiliations: academia (62.8%, 27/43), health-
care facilities (23.2%, 10/43), research institutes (4.7%, 2/43),
consultancies (4.7%, 2/43), and public administration (4.7%,
2/43).
Twenty-four (55.8%) of the 43 studies published state-
ments of financial support. Most of them received financial
support from funding agencies (41.6%, 10/24) and govern-
ments (25.0%, 6/24). The remaining 19 articles (44.2%)
contained no information regarding financial support.
The authors declared conflicts of interest in 16 studies.
However, when we evaluated the studies using the criteria
proposed by Valachis et al. (13), we identified conflicts of
interest in two additional studies. These conflicts of interest
could include receiving remuneration in payment or in kind
(e.g., stocks or shares) from the manufacturer as a result of
any of the following: research support or employment con-
tracts (salary, equipment, supply, reimbursement for partici-
pation in symposia and other expenses) or consulting services.
In the article by David-Neto et al. (22), we identified manu-
facturer financing, which was not disclosed as a conflict of
interest in the original article. Additionally, in the article by
Bacchi et al. (43), we noted that some of the authors were
employed by consulting firms, and this was not disclosed as a
potential conflict of interest in the original article.
Table 2 presents the main methodological characteristics of
the 24 full HEEs, and Table 3 lists their compliance with
recommendations for good reporting.
Ten (41.7%) of the 24 full HEEs reported their main out-
come to be measurements related directly to the diagnosis
strategy, for example, ‘‘case diagnosed’’. The others eval-
uated consequent diagnostic outcomes, such as case averted,
surgery averted, complication averted, life years saved, and
disability-adjusted life years (DALYs) avoided (Table 3). In
one of the HEEs (26), the incremental cost-effectiveness ratio
(ICER) reported was above the threshold of three times the
per capita gross domestic product (GDP) per DALY gained,
and the conclusion of that study regarding the technology
was unfavourable (Table 3). Three studies (39, 54, 59) pre-
sented as their conclusion the measurement of the mean cost-
effectiveness ratio (CER), and two studies (34, 52) only
mentioned that the strategy was dominant without present-
ing ICER calculations.
Most studies clearly stated the research question (100%),
target population (95.8%, 23/24), competing alternatives
(100%), source of effectiveness estimates (95.8%), source of
cost estimates (87.5%, 21/24), and ICER (83.3%, 15/18). How-
ever, only 12.5% (3/24) described the methods used to estimate
the quantities of resources in a correct and transparent manner
and reported them separately from their prices (unit costs).
Only 29.2% (7/24) noted the type of sensitivity analysis, and
33.3% (6/18) described the discount rate applied.
In relation to the measurements of diagnostic effectiveness,
among the 12 CEAs, nine studies (75%) listed the measure-
ments of accuracy (sensitivity and specificity) as epidemio-
logical parameters of the model, and in five of them (55%),
Figure 2 - Growth of HEEs related to diagnostic tests (n=43) in Brazil, 1980-2013.
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the variations in the accuracy measurements were incorpo-
rated into the sensitivity analysis. The only CUA, which used
DALYas an outcome, applied the estimates of sensitivity and
specificity as epidemiological parameters in the decision
model and the variations in these measures in the sensitivity
analysis. Two studies (17%) referred to the application of
methods defined in the literature to check the quality of the
accuracy studies that underpinned the economic model (44, 53).
’ DISCUSSION
To the best of the authors’ knowledge, this is the first
systematic review of Brazilian HEEs in the area of diagnostic
technologies. These HEEs were applied to diverse fields,
including oncology, cardiology, infectious diseases and endo-
crine and metabolic diseases. The studies presented results
that are relevant for decisions taken in clinical and public
health situations in terms of diagnosis (69.8%), and some
analyses were relatively broad, integrating screening and/or
treatment strategies with diagnostic methods.
Regarding the quality of reporting, the Brazilian HEEs
devoted to diagnostic testing performed reasonably well.
Almost all studies satisfactorily stated the research question
(100%), target population (95.8%, 23/24), competing alter-
natives (100%), source of effectiveness estimates (95.8%),
source of cost estimates (87.5%, 21/24), and ICER (83.3%,
15/18). Strong compliance with HEE guidelines was also
reported in a recent study that systematically reviewed all
CUAs addressing diagnostic laboratory testing in the Tufts
Medical Center Cost-Effectiveness Analysis Registry (3).
Nevertheless, some issues still warrant further consideration.
First, only 55.8% (24/43) of the studies declared the funding
source, and second, only 37.2% (16/43) of the studies declared
the potential for any conflict of interest. Missing details on these
two important topics may affect the credibility and transpar-
ency of the results produced by HEE studies.
Three points were identified as requiring special attention
and recommendations for improvement: 1) methods for
estimating resource quantities and unit costs, 2) sensitivity
analysis, and 3) discount rates. A previous review on the
methodological issues of HEEs reached a similar conclusion
in the 1990s, observing that many studies failed to report
important issues, such as the study’s perspective and sen-
sitivity analyses (60).
Brazil published its official health technology assessment
guidelines in 2009. Additionally, in 2011, the use of HEEs
became compulsory for the incorporation of new technolo-
gies in the Brazilian public healthcare system. However, a
clearly stated ‘‘reference case’’ that would increase the con-
sistency of HEE methodology remains lacking. Despite the
substantial number of HEEs produced (61), the local capacity
to develop and use high-quality HEEs still needs to increase.
The lack of technical expertise and the shortage of trained
health economists were also reported in other middle-income
countries (MICs) (62).
Challenges facing those conducting and using economic
evaluations in many MICs include the scarcity, quality and
accessibility of data; insufficient health economic research
capacity; and limited funding. To conduct high-quality
HEEs, far more investment in the training of researchers is
needed, particularly for Master’s degree programmes and
topics such as study design, data collection and analysis.
On-the-job training and mentoring of researchers are also
very important and should be fully funded (63).
Table 1 - General characteristics of HEEs related to diagnostic
tests conducted in Brazil, 1980-2013 (n = 43).
Characteristics N (%)
Type of diagnostic tests
Other laboratory tests* 16 (37.2)
Imaging 14 (32.6)
Set of techniques 5 (11.6)
Rapid tests 3 (7.0)
Algorithms 2 (4.7)
Other (program, physical exam) 2 (4.7)
Cultures of microorganisms 1 (2.3)
Type of diagnostic procedure
Non-invasive 22 (51.2)
Invasive** 20 (46.5)
Does not apply 1 (2.3)
Technology purpose
Diagnosis 30 (69.8)
Diagnosis and treatment 11 (25.6)
Screening, diagnosis and treatment 2 (4.7)
Target population
Adults 21 (48.8)
Not declared 17 (39.5)
Children 2 (4.7)
Adults and children 2 (4.7)
4 12 years 1 (2.3)
Type of study
Full HEEs 24 (55.8)
CEA*** 12 (27.9)
CCA 6 (14.0)
CBA**** 4 (9.3)
CUA 1 (2.3)
CMA 1 (2.3)
Partial HEEs 19 (44.2)
Cost analysis 11 (25.6)
Cost description 8 (18.6)
Journal
National 24 (55.8)
International 19 (44.2)
Region of the country of the first author’s affiliation
South-east 32 (74.4)
South 6 (14.0)
North-east 2 (4.7)
Centro-Oeste 2 (4.7)
North 1 (2.3)
Type of institution of the first author’s affiliation
Academia 27 (62.8)
Health care facility***** 10 (23.2)
Research institute 2 (4.7)
Consultancy 2 (4.7)
Public administration ****** 2 (4.7)
Source of funding
Declared 24 (55.8)
Research funding agency 10 (41.6)
Government 6 (25.0)
Declared no financing 4 (16.6)
Industry 2 (8.3)
International organization 2 (8.3)
Conflicts of interest
Reported 16 (37.2)
Declared no conflicts of interest 16 (100)
Declared conflicts of interest 0 (0.0)
Present, according to Valachis [13] 2 (12.5)
Study conclusion *******
Favourable 17 (70.8)
Neutral 5 (20.8)
Unfavourable 2 (8.3)
*Other laboratory tests: blood test, biopsy, and cytology.
HEEs: health economic evaluations
** Invasive: Those tests that disrupt barriers, such as skin or mucous
membranes.
***One study performed a CEA and a BIA.
****One study performed a CBA and a CMA.
*****Health care facilities: public or private hospitals, blood centres, and
laboratories.
****** Public administration: Ministry of Health, State Health Secretary,
and Municipal Health Secretary.
******* This information was extracted only for the full HEEs (n = 24)
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Diagnostic validity is the definitive stage of technology
evaluations in terms of the probability of true positives
(sensitivity) and true negatives (specificity) relative to a gold-
standard technique. Indeed, measurements of validity are the
principal data that determine the effectiveness of economic
models (64).
Most of the CEAs (75%) reviewed clearly expressed the
measurements of sensitivity and specificity used in the eco-
nomic model, even when the final outcomes of the economic
analysis were not accuracy as such (i.e., in terms of accu-
rate or appropriate diagnoses) but were, instead, measure-
ments arising from accuracy, such as deaths prevented.
Published accuracy studies should be rigorously evalua-
ted for their quality before they can be sued to support
the development of economic models. Two published sets
of guidelines underpin this quality analysis: Quadas 2 and
Stard (65, 66); the former is especially directed towards
evaluations in systematic reviews, whereas the latter is
directed towards reporting in editorial terms. In this review,
only two of the 12 HEEs (17%) cited the quality evaluation of
the accuracy studies from which the parameters of sensitivity
and specificity were extracted. This is an important omission
in these publications and should be part of the reports
because these are basic and essential measurements in cost-
effectiveness results and studies that discuss the costs and
consequences of diagnostic technologies. Indeed, accuracy
measurements are the main parameters that direct the
analytical model, and therefore, methodological weakness
in the estimation of measurements will directly impact the
conclusions of the economic evaluation (9). Furthermore,
evaluations of the quality of the studies underpinning
economic models should be explicit and debated in a
transparent manner (67). These parameters must be subject
to sensitivity analysis because slight variations can strongly
affect the economic conclusions (44).
A review of HEEs of the diagnosis of chronic renal disease
suggested several topics that should be addressed when
conducting economic studies on diagnosis: specification and
clear definition of the measurements of the sensitivity and
specificity of the tests and consideration of the consequences
of including incorrect results in the economic model (6).
In the research protocol ‘‘economic decision models for
genomic testing strategies’’, Peters et al. (2015) commented
that it is rare for economic studies to provide suitable
information about the methods used to evaluate how the
evidence was identified (7). A similar situation was observed
in this review, since only two of the 12 articles on cost-
effectiveness that were reviewed actually described the
evaluation process used to determine the quality of the
primary studies (44, 53).
Otero et al. reviewed HEEs on diagnoses based on images
and determined that the accuracy measurements were
explained in most of the studies evaluated; however, in
23% of the studies, these measurements were not submitted
to a sensitivity analysis. In the Brazilian review, five out of 12
cost-effectiveness studies reviewed and the only CUA varied
in the accuracy measurements used in the sensitivity
analysis. It should be stressed that this finding should be
100% (8).
This review demonstrates that Brazilian HEEs related to
diagnostic tests are reasonably adherent to key recom-
mended general methods for HEEs. However, quality
evaluations of the accuracy studies from which the para-
meters of sensitivity and specificity are extracted is far from
meeting current international standards. If these studies are
to serve as an important source of information for local
decision makers, important issues need to be addressed.
First, they should improve the reporting of the methods used
to estimate resource quantities and unit costs, sensitivity
analysis, discount rate, and conflicts of interest. Second,
the evaluation process used to determine the quality of
the accuracy studies should be explicit and transparent,
and the sensitivity analysis of sensitivity and specificity
parameters should be clearly described. Finally, the accu-
racy measurements are the main parameters that impact
decision analysis models’ results and the conclusions of
HEEs. Thus, they must be both valid and reliable to sup-
port decisions about the incorporation of new diagnostic
technologies in Brazil.
Key Points for Decision Makers
 The Brazilian HEEs in the area of diagnostic technolo-
gies require improvement in the quality of reporting of
1) methods used to estimate resource quantities and unit
costs, 2) discount rates, 3) descriptions of sensitivity analysis
methods, and 4) the reporting of conflicts of interest.
 Decision-making regarding the inclusion of diagnostic
technologies should take into account the quality of the
Table 3 - Methodological quality reporting of HEEs related to
diagnostic tests conducted in Brazil, 1980-2013 (n = 24).
Items N (%)
Study question 24 (100.0)
Target population 23 (95.8)
Study perspective 13 (54.2)
Public Health System 7 (53.8)
Health System (public and private) 3 (23.1)
Public Health System and Society 1 (7.7)
Private Health System 1 (7.7)
Society 1 (7.7)
Comparators 24 (100.0)
Time horizon (n=18)* 8 (44.4)
Lifetime 3 (37.5)
1 year 3 (37.5)
2 years 1 (12.5)
60 days 1 (12.5)
Discount rate (n=18)* 6 (33.3)
Applied to costs and benefits 3 (50.0)
Declared that did not apply 2 (33.3)
Applied to costs 1 (16.7)
Sources for effectiveness estimates 23 (95.8)
Sources for resource use estimates 16 (66.7)
Sources for cost estimates 21 (87.5)
Methods for the estimation of quantities and unit costs 3 (12.5)
Decision analysis model (n=18)* 12 (66.7)
Decision Tree 8 (66.7)
Markov 3 (25.0)
Decision analytical model 1 (8.3)
Not reported 6 (33.3)
Sensitivity analysis 7 (29.2)
Conducted 12 (50.0)
Univariate 3 (25.0)
Univariate and Multivariate 2 (16.7)
Univariate and Probabilistic 1 (8.3)
Univariate, Multivariate and Probabilistic 1 (8.3)
Not reported 5 (41.7)
ICER presentation (n=18)* 15 (83.3)
* This item does not apply to the six cost-consequence studies.
ICER: incremental cost-effectiveness ratio.
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accuracy studies that underpin the economic model and
the sensitivity analyses of sensitivity and specificity para-
meters.
 The sensitivity and specificity parameters must be both
valid and reliable if they are used to support decisions
about the incorporation of new diagnostic technologies in
Brazil.
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